Cargando…

CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation

Introduction: There are still no effective diagnostic and prognostic biomarkers in pancreatic ductal adenocarcinoma (PDAC). The differentiation between PDAC and chronic pancreatitis (CP) is often challenging. The inflammatory mass in the course of CP causes diagnostic difficulties in differentiating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wlodarczyk, Barbara, Durko, Lukasz, Wlodarczyk, Przemyslaw, Talar-Wojnarowska, Renata, Malecka-Wojciesko, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299217/ https://www.ncbi.nlm.nih.gov/pubmed/37373743 http://dx.doi.org/10.3390/jcm12124050

Ejemplares similares

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

The Latest Advancements in Diagnostic Role of Endosonography of Pancreatic Lesions
por: Rogowska, Jagoda Oliwia, et al.
Publicado: (2023)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes
por: Włodarczyk, Barbara, et al.
Publicado: (2020)

Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma
por: Talar-Wojnarowska, Renata, et al.
Publicado: (2020)

The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors
por: Śmigielski, Jacek, et al.
Publicado: (2013)

Pancreatic cyst fluid analysis for differential diagnosis between benign and malignant lesions
por: TALAR-WOJNAROWSKA, RENATA, et al.
Publicado: (2013)

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
por: Winter, Katarzyna, et al.
Publicado: (2019)

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Pancreatic Incidentaloma
por: Caban, Miłosz, et al.
Publicado: (2022)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy
por: Sochal, Marcin, et al.
Publicado: (2021)

Clinical and Laboratory Characteristics of Anaemia in Hospitalized Patients with Inflammatory Bowel Disease
por: Woźniak, Małgorzata, et al.
Publicado: (2023)

Clinical Significance of Erythroferrone and Bone Morphogenetic Protein-6 in Patients with Anemia in the Course of Inflammatory Bowel Disease
por: Woźniak, Małgorzata, et al.
Publicado: (2023)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Dietary Behaviors and Beliefs in Patients with Inflammatory Bowel Disease
por: Godala, Małgorzata, et al.
Publicado: (2023)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods
por: Xu, Qian, et al.
Publicado: (2023)

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
por: Li, Ce, et al.
Publicado: (2019)

Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer
por: Gasiorowska, A., et al.
Publicado: (2015)

Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer
por: Thomas, Divya, et al.
Publicado: (2020)

Relation between Selected Sleep Parameters, Depression, Anti-Tumor Necrosis Factor Therapy, and the Brain-Derived Neurotrophic Factor Pathway in Inflammatory Bowel Disease
por: Sochal, Marcin, et al.
Publicado: (2023)

The Effect of Serotonin Transmission on Depressive and Insomnia Symptoms in Inflammatory Bowel Diseases
por: Sochal, Marcin, et al.
Publicado: (2023)

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration
por: Mijatovic, Tatjana, et al.
Publicado: (2007)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
por: Almeida, Palloma Porto, et al.
Publicado: (2020)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
por: Yin, Wenke, et al.
Publicado: (2023)

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
por: Durko, L., et al.
Publicado: (2017)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Corrigendum to “Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis”
por: Durko, L., et al.
Publicado: (2017)

Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC)
por: Zińczuk, Justyna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r0qpoaf068sm9vkq8pkl464n2h